Sunday , April 22 2018
Home / 2017

Yearly Archives: 2017

Patients Treated with Sarepta’s Eteplirsen Experienced a Reduction in Pulmonary Decline in Duchenne Muscular Dystrophy Study

CAMBRIDGE, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that the pulmonary function results from eteplirsen-treated Duchenne muscular dystrophy (DMD) patients (N=12) in Study 201/202 compared …

Read More »

Innovation Pharmaceuticals Obtains Evidence of Molecular Pathways Modulation in Tumors from Patients in Kevetrin Mid-Stage Ovarian Cancer Trial

BEVERLY, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce highly encouraging preliminary data from the first patients treated in the Company’s Phase 2a clinical trial (see NCT03042702) of Kevetrin for ovarian cancer. Modulation of the p53 …

Read More »

HTG Molecular Diagnostics Expands Collaboration with Merck KGaA

TUCSON, Ariz. and DARMSTADT, Germany, Dec. 26, 2017 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications today announced a new Master Collaboration Agreement for translational programs with Merck KGaA, Darmstadt, Germany, a leading science and technology company. The Master Collaboration …

Read More »

INSYS’ Cannabidiol Solution Receives FDA Fast Track Designation as Treatment for Prader-Willi Syndrome

PHOENIX, Dec. 26, 2017 (GLOBE NEWSWIRE) — INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder characterized by insatiable appetite in children that …

Read More »

FDA Grants Orphan Drug Designation to Organovo’s 3D Bioprinted Therapeutic Liver Tissue Treatment of Alpha-1 Antitrypsin Deficiency

SAN DIEGO, Dec. 26, 2017 (GLOBE NEWSWIRE) — Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) today announced that the U.S. Food and Drug Administration (“FDA”) granted orphan drug designation for the Company’s treatment of alpha-1 antitrypsin deficiency (“A1AT”) with its 3D bioprinted liver therapeutic tissue. “We are extremely pleased to receive orphan …

Read More »

Study Explores Impact of Obesity on Bone Marrow Cells

CINCINNATI, Dec. 27, 2017 /PRNewswire-USNewswire/ — New research published in the Journal of Experimental Medicine highlights the pernicious effect of obesity on the long-term health of blood-making stem cells (hematopoietic stem cells). Published Dec. 27, the study was led by researchers at the Cincinnati Children’s Cancer and Blood Diseases Institute. …

Read More »

FDA Grants Fast Track Designation to DelMar’s Recurrent Glioblastoma Candidate

VANCOUVER, British Columbia and MENLO PARK, Calif., Dec. 26, 2017 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for …

Read More »

FDA Updates Label of Novartis’ Tasigna to Include Treatment-Free Remission Data

EAST HANOVER, N.J., Dec. 22, 2017 /PRNewswire/ — Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna® (nilotinib) US product label. Tasigna is now the first and only BCR-ABL tyrosine kinase inhibitor (TKI) to include data about …

Read More »

Mallinckrodt to Acquire Sucampo Pharmaceuticals for $1.2 Billion

STAINES-UPON-THAMES, United Kingdom and ROCKVILLE, Md., Dec. 26, 2017 /PRNewswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, and Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a global biopharmaceutical company, today announced that they have entered into an agreement under which Mallinckrodt will acquire Sucampo, including its commercial and …

Read More »

Roche to Acquire Cancer Medicine Specialist Ignyta for $1.7 Billion

SAN DIEGO–(BUSINESS WIRE)–Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ …

Read More »